enGene Therapeutics Inc. ENGN
1.68 USD +0.06 (+3.70%)
Nov 4, 2026, 11:33 AM EST
1.58 Day range 1.69
1.40 52-week range 12.25
- YTD
- -81.40%
- 1 year
- -74.27%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 27.00 +1507.1% upside
Now 1.68
- Target (low)
- 16.00
- Target (mean)
- 27.00
- Target (high)
- 37.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
- Strong buy4
- Buy5
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 9
- 1 month ago 8
- 2 months ago 6
- 3 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.3825 | -0.43 – -0.31 | -0.46 | +16.9% | 0 | 0.0% | 8 |
| Next quarter | -0.4025 | -0.45 – -0.32 | -0.38 | -5.9% | 0 | 0.0% | 8 |
| Current year | -1.62 | -1.84 – -1.30 | -1.46 | -11.2% | 0 | 0.0% | 9 |
| Next year | -2.01 | -2.28 – -1.57 | -1.62 | -24.1% | 7.17M | 0.0% | 8 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Dec 23, 2024 | HC Wainwright & Co. | Initiated | — | Buy |
| Dec 6, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Nov 27, 2024 | Raymond James | Initiated | — | Outperform |
| Nov 18, 2024 | JMP Securities | Initiated | — | Market Outperform |
| Sep 24, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Sep 11, 2024 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 28, 2024 | Oppenheimer | Initiated | — | Outperform |
| Apr 22, 2024 | Wells Fargo | Initiated | — | Overweight |
| Apr 15, 2024 | Guggenheim | Initiated | — | Buy |
| Mar 28, 2024 | UBS | Initiated | — | Buy |
| Mar 8, 2024 | Morgan Stanley | Initiated | — | Overweight |